Monday, September 7, 2009

R P Phase 2 trial ended could this be the break we need???

We are pleased to announce that subject enrollment for the phase 2 clinical
study of 0.15% UF-021 (generic name; isopropyl unoprostone; active ingredient of
Rescula(R) eye-drops) in patients with retinitis pigmentosa has been

We submitted the notification of the clinical trial in August 2008.
Enrollment in the phase 2 study began at six clinical sites in late December
2008 and was completed on August 3, 2009.

The clinical study has progressed with no delay, no serious adverse effects,
and only a few cases of discontinuation so far. Hereafter, we expect to complete
the study by next spring, including data collection and analysis.

Retinitis pigmentosa is a progressive hereditary disease affecting nearly
50,000 people in Japan, which is characterized by night blindness. Patients
generally suffer from peripheral visual field loss and low vision in the late
stage of the disease. At present, there is no effective treatment for this

We developed and launched isopropyl unoprostone eye-drops on the market as a
drug for glaucoma and ocular hypertension in 1994.
In recent studies on isopropyl unoprostone, the drug has been reported to
present neuroprotective effects and a function to improve ocular circulation.
Studies at some university hospitals have also suggested that isopropyl
unoprostone eye-drops improve symptoms of retinitis pigmentosa or stop the
progression of the disease.

We expect isopropyl unoprostone to become a unique drug for improvement of
the quality of vision in patients with retinitis pigmentosa.

No comments:

Post a Comment

Please leave comments or questions